Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ATIC | P31939 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679141 | 0.80 | ALOX15 (0.55) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL29903216 | 0.80 | ALOX15 (0.55) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL17491070 | 0.74 | ALOX15 (0.40) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL27514891 | 0.73 | EZH2 (0.44) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL27642034 | 0.72 | KDM4E (0.41) | ALOX15GAAPOLBEZH2HTT | |
| SCHEMBL28020138 | 0.72 | ALOX15 (0.52) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL453481 | 0.71 | ALOX15 (0.48) | ALOX15GAAKMT2APOLBEZH2 | |
| Phthalic Acid SCHEMBL11485468 | 0.70 | ALOX15 (0.61) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL16749053 | 0.70 | ALDH1A1 (0.44) | ALOX15GAAKMT2APOLBEZH2 | |
| SCHEMBL17509215 | 0.70 | GAA (0.47) | GAAKMT2APOLBEZH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982731-B1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-9643924-B2 | Piperidine derivative, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160039758-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2982731-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039758-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, CCND1 | ALOX15 1458/4885GAA 4581/4885KMT2A 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.